DEPLOYDatabase

Company

Distalmotion

Distalmotion is a Swiss surgical robotics company based in Lausanne, developing the Dexter robotic surgery system for minimally invasive abdominal surgery,…

Founded
2012
HQ
Lausanne, Switzerland
Status
private (raised $150M Nov 2025)

Models

1

Overview

Distalmotion is a Swiss surgical robotics company based in Lausanne, developing the Dexter robotic surgery system for minimally invasive abdominal surgery, combining remote-center motion with a compact, ergonomic surgical platform.

Verified record

Verified deployments
None on file
Active incidents
1 incident on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

Dexter hybrid laparoscopic surgical robot (robotic <-> manual mid-procedure); ASC cost-efficiency.

Gating events

CE Dec 2020; FDA De Novo Oct 2024 (inguinal hernia) + cholecystectomy + hysterectomy.

Origin

EPFL spinout

Patients treated

~3,000 patients

Data & sources

Press releases

1

Web sources

3

4 sources backing this record.View all →

Distalmotion on the deployment map

Where Distalmotion's robots are verified operating. Explore the deployment map by place and type.

Explainers

Plain-language answers to the questions people ask about Distalmotion, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is a surgical robot?

    A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.

Current leadership (2)

Founders (2)

Board (2)

Safety record

1 incident on record (1 minor). Most recent: Jun 2026.

minor
1

Most recent: Jun 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Distalmotion (1)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Recent coverage

Distalmotion in third-party press

Peer companies